SCHEMBL3562089

SCHEMBL3562089

CCCC[Sn](CCCC)(CCCC)c1cn(-c2nc(-c3ccc(F)cc3)cc(C(F)(F)F)n2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.47
MAPK1 P28482 3/20 0.47
HSD17B10 Q99714 3/20 0.47
TSHR P16473 1/20 0.47
TP53 P04637 4/20 0.46
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
MAPT P10636 6/20 0.44
POLB P06746 1/20 0.44
PTGS2 P35354 5/20 0.41
TDP1 Q9NUW8 3/20 0.41
PTGS1 P23219 2/20 0.41
KMT2A Q03164 1/20 0.41
MITF O75030 1/20 0.40
LMNA P02545 1/20 0.40
STAT3 P40763 1/20 0.40
STAT1 P42224 1/20 0.40
RAB9A P51151 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TLR9 Q9NR96 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3559997 0.92 KDM4E (0.41) KDM4EMAPK1HSD17B10TSHRTP53
SCHEMBL3562590 0.91 KDM4E (0.39) KDM4EMAPK1HSD17B10TSHRTP53
SCHEMBL3560227 0.91 KDM4E (0.42) KDM4EMAPK1HSD17B10TSHRTP53
SCHEMBL3570673 0.87 KDM4E (0.38) KDM4EMAPK1HSD17B10TSHRALDH1A1
SCHEMBL3557460 0.87 KDM4E (0.37) KDM4EMAPK1HSD17B10TSHRALDH1A1
SCHEMBL3557741 0.82 TLR8 (0.40) KDM4EALDH1A1SMN1; SMN2MAPTPTGS2
SCHEMBL3562592 0.76 ENPP2 (0.38) KDM4EALDH1A1POLBKMT2ARAB9A
SCHEMBL3568035 0.76 KDM4E (0.56) KDM4EMAPK1HSD17B10TSHRTP53
SCHEMBL3564740 0.76 TLR8 (0.41) KDM4EHSD17B10TSHRALDH1A1PTGS2
SCHEMBL3568140 0.75 TLR8 (0.36) KDM4EALDH1A1PTGS2PTGS1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2001849-B1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2014-11-26 EP disclosed
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 KDM4E 2568/4885MAPK1 2283/4885HSD17B10 3931/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 KDM4E 1276/4885MAPK1 1426/4885HSD17B10 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.